Novo Nordisk Re-evaluates Risk Strategy as Executives Push for Expansion Beyond Weight-Loss Drugs

Novo Nordisk executive Mike Doustdar signals an aggressive shift toward large corporate deals and higher-risk ventures to diversify away from its dominant weight-loss products.

Loading lens…